JMT106

JMT106 is a recombinant humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR), developed by Shanghai JMT-Bio, a subsidiary of CSPC Pharmaceutical Group. EGFR is a transmembrane glycoprotein that plays a critical role in cell growth, differentiation, and survival; its overexpression or mutation is frequently associated with various malignancies, including lung and liver cancers. JMT106 works by binding to the extracellular domain of EGFR, thereby blocking the binding of ligands such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α). This inhibition prevents receptor dimerization and subsequent activation of intracellular tyrosine kinase signaling pathways, including the MAPK, PI3K/Akt, and STAT pathways, which are essential for tumor progression. Additionally, as a monoclonal antibody, JMT106 may facilitate immune-mediated tumor cell lysis through antibody-dependent cellular cytotoxicity (ADCC). It is currently undergoing Phase I clinical evaluation for the treatment of advanced solid tumors, with a specific focus on lung squamous cell carcinoma and hepatocellular carcinoma.